United Kingdom Bioidentical Hormones Market Insight
United Kingdom Bioidentical Hormones Market is growing at an 6.53% CAGR, driven by rising menopause awareness, personalized hormone therapies, improved diagnostics, and growing demand for natural treatments.
United Kingdom Bioidentical Hormones Market Insights Forecasts to 2035
- The United Kingdom Bioidentical Hormones Market Size Was Estimated at USD 221.2 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 6.53% from 2025 to 2035
- The United Kingdom Bioidentical Hormones Market Size is Expected to Reach USD 416.3 Million by 2035
Notable Insights for United Kingdom Bioidentical Hormones Market
- By hormone type, oestrogen bioidentical therapies dominated, accounting for approximately 45% share in 2024, driven by high adoption in menopause management.
- By dosage form, transdermal creams and gels dominated, holding approximately 55% share, due to convenience, steady hormone absorption, and patient preference.
- Approximately 20% of women in the UK experience moderate-to-severe menopausal symptoms requiring hormonal management, supporting demand for bioidentical hormone therapies.
Download the eBook (ToC)
- Around 70% of patients receiving bioidentical hormone therapy prefer customized or compounded formulations tailored to individual hormonal profiles and symptom management.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Bioidentical Hormones Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Bioidentical Hormones Market
- Novo Nordisk
- Abbott Laboratories
- Pfizer
- Viatris
- Besins Healthcare
- Theramex
- Bayer
- Gedeon Richter
- Fagron
- Others
Recent Developments:
- In May 2025: UK specialists, including The Marion Gluck Clinic, expanded personalized bioidentical hormone optimization using advanced testing and tailored dosing for menopause, perimenopause, and andropause management.
- In March 2024: The British Menopause Society emphasized growing UK adoption of regulated body-identical hormone therapies, highlighting their safety, efficacy, and increasing preference over unregulated compounded bioidentical hormone treatments.
Market Segmentation:
United Kingdom Bioidentical Hormones Market, By Hormone Type
- Oestrogen
- Progesterone
- Testosterone
- Combination Hormones
- Others
United Kingdom Bioidentical Hormones Market, By Dosage Form
- Tablets and capsules
- Creams and gels
- Injectables
- Patches and implants
- Others
United Kingdom Bioidentical Hormones Market, By End User
- Hospitals
- Gynaecology clinics
- Research laboratories
- Others
United Kingdom Bioidentical Hormones Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Channels
Expert Views:
The United Kingdom Bioidentical Hormones Market is forecasted to grow steadily due to the heightened awareness of menopause, growing preference for customized hormone therapy, and increased accessibility of women's health care facilities. It is widely believed by experts that estrogen and progesterone-based treatments will continue to dominate the market because of their safe and natural ingredients. Investments in hormone research and compounded hormone products are predicted to drive future market growth up until 2035.